Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/247857
Share/Export:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Appraising screening, making risk in/visible. The medical debate over Non-Rare Thrombophilia (NRT) testing before prescribing the pill [DATASET]

AuthorsTurrini, Mauro CSIC ORCID CVN ; Bourgain, Catherine
KeywordsVisibility
Risk
Screening
Controversy
Hormonal contraception
Medical profession role
Adverse drug reactions
Issue Date11-Aug-2021
PublisherDIGITAL.CSIC
CitationTurrini, Mauro; Bourgain, Catherine; 2021; Appraising screening, making risk in/visible. The medical debate over Non-Rare Thrombophilia (NRT) testing before prescribing the pill [DATASET]; DIGITAL.CSIC; http://dx.doi.org/10.20350/digitalCSIC/13972
AbstractNon-rare thrombophilias (NRT) are hereditary predispositions to thromboembolism, the most severe side-effect of hormonal contraception. In the mid-1990s, the identification of NRT stirred up a controversy over the possibility of investigating these genetic variants in women wishing to use contraception. Appraising how to handle this test led the medical profession to reconfigure the risk visibility on hormonal contraception. Through a review of scientific literature, this paper reconstructs the debate over whether and how NRT genetic tests should enter the distribution system of pharmacological contraception. The main arguments concern their epidemiological, social, economic, and clinical consequences of these risk factors. We analyze this debate as a process consisting in shaping the risk visibility. To those who opt for selective thrombophilia screening, this test should become a part of the medical decision-making process, and its visibility should be kept under medical control to protect contraception safety. To advocates of universal or “extended” screening, NRT visibility becomes a moral/legal obligation, and the test a valuable, if not mandatory, means to assure contraception safety. Risk visibility reveals assumptions about medical power, women’s responsibility, and drug safety, and points to an appraisal process as an ideal field to explore political and epistemological implications of screening.
DescriptionThe dataset includes: - a detailed description of the search procedure, the queries adopted, and selection criteria of selection exclusion (section #1); - the two original bibliographic searches (section #2 & #3); - the final 21 articles selected coming from these searches and 7 additional articles coming from manual searches of literature reviews (section #4).
URIhttp://hdl.handle.net/10261/247857
DOI10.20350/digitalCSIC/13972
ReferencesTurrini, M., & Bourgain, C. Appraising screening, making risk in/visible. The medical debate over Non-Rare Thrombophilia (NRT) testing before prescribing the pill. Sociology of Health & Illness. 2021; 00: 1– 16. https://doi.org/10.1111/1467-9566.13348 http://hdl.handle.net/10261/247674
Appears in Collections:(CCHS-IPP) Conjuntos de datos




Files in This Item:
Show full item record
Review this work

Page view(s)

111
checked on Jul 2, 2022

Download(s)

60
checked on Jul 2, 2022

Google ScholarTM

Check

Altmetric

Dimensions


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.